Afternoon Symposium: Statistical Innovations in Clinical Trials Thursday, February 26, 1:30PM - 5:30PM (Pacific Time) with presentation from 2:00PM to 4:30PM. Time before and after presentation is used for mingle and reception. Break time will be provided for the presentation if necessary.
Gilead Sciences, 333 Lakeside Dr, Foster City, CA, 94404.
The San Francisco Bay Area Chapter of American Statistical Association (www.sfasa.org) and Cytel have a forum on how innovative statistical approaches are transforming drug, biologic and device development. This is an ideal opportunity to learn more about strategically employing adaptive designs to align with your clinical development goals. Gilead Sciences has kindly offered to host this seminar, but space is limited, so please register today by clicking the following register link.
Learn more and register
Join us on the afternoon of February 26th to learn:
• How adaptive methods can mitigate development risks in the face of tight resource constraints
• Why certain approaches were chosen over other potential strategies
• How to overcome operational challenges posed by more innovative trial designs
Adaptive Design in Survival Analysis Jin Wang, Principal Research Statistician, Abbott Vascular "Adaptive strategy in survival analysis is in general more complex than other applications. This talk will review some recent development in this area…" Read More
Gene coexpression measures in large heterogeneous samples using count statistics
Haiyan Huang, Associate Professor, Department of Statistics, UC Berkeley
Determining Treatment Effect with Biomarkers and Group Sequential Boundaries Eric Holmgren, Director of Biostatistics, OncoMed "Using stopping boundaries from group sequential trials, we control the overall type 1 error when evaluating the treatment effect in each of several predefined marker subgroups..." Read More
Statistical and Operational Challenges of VALOR, an Adaptive Phase-3 Trial for Acute Myeloid Leukemia Cyrus Mehta, President & Co-Founder, Cytel Jennifer Smith, Executive Director Biometrics, Sunesis Pharmaceuticals "Recently completed VALOR accrued 711 patients, and comprises the largest AML body of evidence from a randomized Phase 3 clinical trial. This adaptive event driven trial was designed..." Read More
Registration is $40. The fee is waived for students.
Questions? Email Shariq Alavi in the Bay Area or call: 857-928-6230
Return to www.sfasa.org